OR WAIT null SECS
May 13, 2022
Through a collaboration, Avantor and Cytovance Biologics will accelerate plasmid optimization and sourcing services for viral vectors and mRNA-based vaccines and therapeutics.
May 11, 2022
Further development of nucleic acid-based therapeutics has been accelerated by the recent success of mRNA vaccines.
April 27, 2022
GeoVax has received a patent for its malaria vaccine from the US Patent and Trademark Office.
April 15, 2022
GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9 billion.
April 13, 2022
With high-concentration biologics, careful selection of excipients in formulation is crucial for reducing viscosity without destabilizing the protein.
April 11, 2022
Ymmunobio AG has signed a patent purchase agreement with LeukoCom GmbH to expand its development of cancer therapies.
Pfizer plans to acquire ReViral and its respiratory syncytial virus therapeutic candidates to strengthen Pfizer’s capabilities in infectious disease research.
Lonza and Asher Biotherapeutics have entered a manufacturing agreement for a cis-targeted IL-2 fusion protein, AB359.
April 08, 2022
Evonetix’s thermally controlled DNA synthesis technology is designed to enable highly parallel DNA synthesis in a benchtop platform.
NIH has announced four new grant awards to fund new tuberculosis research advancement centers.